Celeste P.
- Country
- Denmark
- Department
- Department of Respiratory Medicine & Infectious Diseases, Bispebjerg & Frederiksberg Hospital
Research Overview
- Effect of Tezepelumab on epithelial TSLP induction after viral mimic stimulation in severe asthma with and without chronic rhinosinusitis
- Evaluation of Itepekimab's Mechanism of Action on Airway Inflammation in Chronic Obstructive Pulmonary Disease: A Phase 2a Open-Label Study
- Evaluation of Benralizumab on Structural and Lung Function Alterations in Severe Eosinophilic Asthma: A Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 98 of 260 partner sites.
Specializations
Respiratory Diseases
The investigator specializes in treating severe respiratory conditions, with particular emphasis on severe eosinophilic asthma and chronic obstructive pulmonary disease (COPD).
- Severe Asthma Management
- COPD Treatment Innovations
- Airway Inflammation Studies
Their work involves evaluating structural and functional changes in airways using advanced imaging techniques.
Inflammatory Conditions
The investigator focuses on eosinophilic disorders and their impact on respiratory health, particularly examining submucosal eosinophils and their role in disease progression.
- Eosinophilic Inflammation
- Airway Wall Assessment
- Inflammatory Biomarkers
Their expertise extends to studying inflammatory patterns in both current and former smokers.
Therapeutic Applications
The investigator examines novel therapeutic approaches for respiratory conditions, particularly focusing on biological treatments for severe airway diseases.
- Exacerbation Management
- Gene Expression Analysis
- Advanced Imaging Studies
Their research encompasses quantitative computed tomography imaging and molecular analysis techniques.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.